LENZ Therapeutics (LENZ) Income from Continuing Operations (2020 - 2026)
LENZ Therapeutics (LENZ) reported Income from Continuing Operations of 41491000.0 for Q1 2026, down 184.03% year-over-year from 49376825.09 in Q1 2025, and down 15.59% on a QoQ basis from 35896000.0 in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Income from Continuing Operations data on file, last reported at 41491000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 184.03% year-over-year to 41491000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 108999000.0 (down 128.37% YoY) and the FY2025 annual result came in at 82127000.0, down 65.02% from the prior year.
- Income from Continuing Operations retreated to 41491000.0 in Q1 2026 per LENZ's latest filing, from 35896000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 10215000.0 in Q3 2024 and bottomed at 41491000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 16700000.0 (2025), against an average of 20465176.47.
- The widest annual swing landed in 2023, when Income from Continuing Operations soared 51.4%; it then plunged 184.03% in 2026.
- Tracing LENZ's Income from Continuing Operations over 5 years: stood at 26751000.0 in 2022, then climbed by 9.77% to 24138000.0 in 2023, then surged by 47.58% to 12652000.0 in 2024, then tumbled by 183.72% to 35896000.0 in 2025, then decreased by 15.59% to 41491000.0 in 2026.
- Per Business Quant, the three latest LENZ Income from Continuing Operations figures stand at 41491000.0 (Q1 2026), 35896000.0 (Q4 2025), and 16700000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | -41.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.49 Mn |
| Dec 31, 2025 | -35.90 Mn |
| Sep 30, 2025 | -16.70 Mn |
| Jun 30, 2025 | -14.91 Mn |
| Mar 31, 2025 | -14.61 Mn |
| Dec 31, 2024 | -12.65 Mn |
| Sep 30, 2024 | -10.22 Mn |
| Jun 30, 2024 | -10.25 Mn |
| Mar 31, 2024 | -15.30 Mn |
| Dec 31, 2023 | -24.14 Mn |
| Sep 30, 2023 | -18.78 Mn |
| Jun 30, 2023 | -14.71 Mn |
| Mar 31, 2023 | -12.62 Mn |
| Dec 31, 2022 | -26.75 Mn |
| Sep 30, 2022 | -26.15 Mn |
| Jun 30, 2022 | -26.78 Mn |
| Mar 31, 2022 | -25.96 Mn |
| Dec 31, 2021 | -18.94 Mn |
| Sep 30, 2021 | -14.60 Mn |
| Jun 30, 2021 | -17.53 Mn |
| Mar 31, 2021 | -9.37 Mn |
| Dec 31, 2020 | -8.32 Mn |
| Sep 30, 2020 | -3.76 Mn |
| Jun 30, 2020 | -1.31 Mn |